Clinical-stage biopharmaceutical company Prelude Therapeutics announced a clinical trial collaboration with BeiGene, a global biotechnology company, to investigate the efficacy of its experimental CDK9 inhibitor, PRT2527, along with BeiGene's BTK inhibitor, zanubrutinib, in the treatment of blood cancers. 

PRT2527 is an investigational drug that belongs to the class of CDK9 inhibitors that are being studied for their potential use in cancer therapy. CDK9 is a protein involved in regulating cell growth and division and is found to be overactive in certain types of cancers. Inhibiting its activity can disrupt the growth and survival of cancer cells. PRT2527 is being developed by Prelude Therapeutics for the treatment of various types of cancer, including hematologic malignancies.

Under the terms of the clinical trial collaboration agreement, BeiGene will supply zanubrutinib to Prelude while Prelude will maintain complete global responsibility and control over the development, operation, and commercialization of PRT2527.

North Carolina-based Prelude Therapeutics is a clinical-stage precision oncology company focused on creating drug candidates by targeting specific pathways in cancer cells. Currently, the pipeline includes four candidates in Phase I clinical trials: PRT1419, an inhibitor of MCL1; PRT2527, an inhibitor of CDK9; PRT3645, a CDK4/6 inhibitor of the next generation; and PRT3789, the first protein degrader of SMARCA2/BRM in its class.